Product Information
METFORMIN HCL 850 MG TABLET is a generic product labeled by Granules Pharmaceuticals Inc., priced at $0.0240 per EA under NDC 70010006401. Its NADAC has been published 330 times since Jun 10, 2020.
FDA first approved this application on Apr 22, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
850 mg/1
Manufacturer
Granules Pharmaceuticals Inc.NDC
70010006401
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
METFORMIN HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA090564FDA Approved
4/22/2010
TE Code
AB
On Market Since
6/26/2019
Pharmacological Classes
Price Statistics
The NADAC for METFORMIN HCL 850 MG TABLET has been published 330 times since Jun 10, 2020, and over the history we have for it it has declined 15.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0240 per EA |
|---|---|
| All-time high | $0.0312 (Aug 12, 2020) |
| All-time low | $0.0196 (May 22, 2024) |
| 52-week high | $0.0248 |
| 52-week low | $0.0224 |
| Median price | $0.0265 |
| Average price | $0.0262 |
| Largest weekly change | +26.0% (Jun 19, 2024) |
| Weeks tracked | 330 |
| Tracking since | Jun 10, 2020 |
Generic Alternatives
The matcher finds 13 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Granules Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Metformin Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Biguanide class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of METFORMIN HCL 850 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for METFORMIN HCL 850 MG TABLET, manufactured by Granules Pharmaceuticals Inc., is $0.0240 per EA (NDC 70010006401), effective Sep 30, 2026.
How has the price of METFORMIN HCL 850 MG TABLET changed over time?
Over the history we have for it, the NADAC for METFORMIN HCL 850 MG TABLET has declined 15.7%. It has been tracked across 330 weekly CMS publications since Jun 10, 2020.
What are the highest and lowest recorded NADAC prices for METFORMIN HCL 850 MG TABLET?
Since Jun 10, 2020, the NADAC for METFORMIN HCL 850 MG TABLET has ranged from a low of $0.0196 (May 22, 2024) to a high of $0.0312 (Aug 12, 2020), with a median of $0.0265 per EA.
Are there cheaper alternatives to METFORMIN HCL 850 MG TABLET?
Yes. 13 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, METFORMIN HCL 850 MG TABLET, is $0.0239 per EA — about 0% below METFORMIN HCL 850 MG TABLET.
Who manufactures METFORMIN HCL 850 MG TABLET?
METFORMIN HCL 850 MG TABLET (NDC 70010006401) is labeled by Granules Pharmaceuticals Inc., and CMS classifies it as a generic product.